Medical Company Spectral Medical Inc. (TSX: EDT, OTC: EDTXF, Forum) released its Q2 2019 financial results on Thursday, highlighting revenues of $1,041,000, compared to $234,000 for the same period last year.
For more revenue highlights, click here.
Seeking US FDA approval for its unique product to treat septic shock, Spectral recently provided investors an updateon both the start-up of the Tigris trial as well as developments in Dialco, a wholly-owned subsidiary of Spectral.
FULL DISCLOSURE: Spectral Medical Inc. is a client of Stockhouse Publishing.